Ethereum co-founder Vitalik Buterin supports EIP-8288, a draft proposal to improve how Ethereum verifies complex cryptographic operations. Instead of verifying every signature or proof individually on-chain, EIP-8288 suggests aggregating multiple cryptographic proofs off-chain and submitting a single combined proof for validation. This approach aims to reduce the data and computational load on Ethereum's network, enabling support for advanced cryptography like quantum-resistant signatures without frequent protocol upgrades. The proposal remains under development and requires network consensus before implementation.
Ethereum cryptography improvements are the focus of Vitalik Buterin's proposal, with Pluang providing market context for cryptocurrencies as of Oct 19, 2026 16:01 WIB. Among 50 major cryptocurrencies priced on Pluang, 37 rose and 11 fell today. Notable movers include DOT at Rp20.200 with a 1-day change of +2.25% and a Pluang order activity of 11% Sell / 89% Buy, XRP at Rp23.631 with a 1-day change of +2.17% and order activity near balanced at 49% Sell / 51% Buy, and ENJ at Rp491 with a 1-day change of -2.15% and heavy sell activity at 95% Sell / 5% Buy.
Nyxoah announced preliminary Q3 2026 revenue of €9.2 million, up 19% sequentially, driven by a 29% increase in U.S. sales. The company submitted a PMA supplement to the FDA to expand its Genio device indication for patients with complete concentric c...
ASML Holding N.V. announced recent transactions under its ongoing share buyback program, repurchasing a total of 233,867 shares between October 12 and October 16, 2026. The shares were bought back at weighted average prices ranging from €1,444.83 to ...
The Phase 3 ALKIVIA trial demonstrated that efgartigimod significantly improves symptoms in patients with autoimmune myositis, including immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). Patients showed meaningful clinical improve...
In 2025, Berkshire Hathaway, led by Greg Abel, received $479 million in dividends from its $1.3 billion investment in American Express. This highlights the value of holding strong dividend-paying stocks for steady income. Retail investors can apply s...
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
